This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yue, W. Articles by Brodie, A. Search for Related Content PubMed PubMed Citation Articles by Yue, W. Articles by Brodie, A.

Effect of Aromatase Inhibitors on Growth of Mammary Tumors in a Nude Mouse Model¹

Department of Pharmacology and Experimental Therapeutics, School of Medicine, University of Maryland, Baltimore, Maryland 21201

The effects of aromatase inhibitors 4-hydroxyandrostenedione (4-OHA), CGS 16949A, and CGS 20267, and of the antiestrogen tamoxifen (TAM), were studied on the growth of human breast carcinoma in a nude mouse model. To simulate the postmenopausal breast cancer patient, tumors were formed from inoculates of MCF-7 cells transfected with the human aromatase gene to provide a source of non-ovarian estrogen in ovariectomized mice. Tumor growth was significantly inhibited by all treatments (P < 0.05). Greater reduction in growth occurred in mice treated with TAM combined with aromatase inhibitors than with TAM alone. Tumor progesterone receptor concentrations were unaltered by TAM treatment but were reduced by aromatase inhibitors. Progesterone receptor concentrations correlated with tumor growth. The greatest reduction occurred in tumors of CGS 20267-treated mice in which no progesterone receptors were detected. In the ovariectomized mice used in these studies, uterine weight was maintained by estrogen produced from the tumor. Uterine weight was reduced by aromatase inhibitors but not by TAM treatment. However, there was a significant increase in uterine weight in mice treated with the combination of TAM and 4-OHA. Thus, the agonist effect of TAM was evident when estrogen synthesis was inhibited. The results indicate that aromatase inhibitors have potent effects on mammary tumor growth but lack the estrogenic effects on the uterus observed with TAM. There appeared to be no significant benefit in combining TAM with 4-OHA over 4-OHA treatment alone.

¹ This work was supported by NIH Grant CA 62483.

² To whom requests for reprints should be addressed, at Department of Pharmacology and Experimental Therapeutics, University of Maryland School of Medicine, 655 West Baltimore Street, Baltimore, MD 21201-1559.

Received 1/ 9/95. Accepted 5/16/95.

This article has been cited by other articles:

				C. A. A. Penatti, D. M. Porter, and L. P. Henderson Chronic Exposure to Anabolic Androgenic Steroids Alters Neuronal Function in the Mammalian Forebrain via Androgen Receptor- and Estrogen Receptor-Mediated Mechanisms J. Neurosci., October 7, 2009; 29(40): 12484 - 12496. [Abstract] [Full Text] [PDF]

				R. J. Santen, H. Brodie, E. R. Simpson, P. K. Siiteri, and A. Brodie History of Aromatase: Saga of an Important Biological Mediator and Therapeutic Target Endocr. Rev., June 1, 2009; 30(4): 343 - 375. [Abstract] [Full Text] [PDF]

				S. M. Belcher, X. Ma, and H. H. Le Blockade of Estrogen Receptor Signaling Inhibits Growth and Migration of Medulloblastoma Endocrinology, March 1, 2009; 150(3): 1112 - 1121. [Abstract] [Full Text] [PDF]

				P. A. Foster, S. K. Chander, S. P. Newman, L.W. L. Woo, O. B. Sutcliffe, C. Bubert, D. Zhou, S. Chen, B. V.L. Potter, M. J. Reed, et al. A New Therapeutic Strategy against Hormone-Dependent Breast Cancer: The Preclinical Development of a Dual Aromatase and Sulfatase Inhibitor Clin. Cancer Res., October 15, 2008; 14(20): 6469 - 6477. [Abstract] [Full Text] [PDF]

				L. F. Macedo, G. J. Sabnis, O. G. Goloubeva, and A. Brodie Combination of Anastrozole with Fulvestrant in the Intratumoral Aromatase Xenograft Model Cancer Res., May 1, 2008; 68(9): 3516 - 3522. [Abstract] [Full Text] [PDF]

				G. Sabnis, O. Goloubeva, D. Jelovac, A. Schayowitz, and A. Brodie Inhibition of the Phosphatidylinositol 3-Kinase/Akt Pathway Improves Response of Long-term Estrogen-Deprived Breast Cancer Xenografts to Antiestrogens Clin. Cancer Res., May 1, 2007; 13(9): 2751 - 2757. [Abstract] [Full Text] [PDF]

				Y. H. Ju, K. F. Allred, C. D. Allred, and W. G. Helferich Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations Carcinogenesis, June 1, 2006; 27(6): 1292 - 1299. [Abstract] [Full Text] [PDF]

				D. Jelovac, G. Sabnis, B. J. Long, L. Macedo, O. G. Goloubeva, and A. M.H. Brodie Activation of Mitogen-Activated Protein Kinase in Xenografts and Cells during Prolonged Treatment with Aromatase Inhibitor Letrozole Cancer Res., June 15, 2005; 65(12): 5380 - 5389. [Abstract] [Full Text] [PDF]

				D. Jelovac, L. Macedo, O. G. Goloubeva, V. Handratta, and A. M.H. Brodie Additive Antitumor Effect of Aromatase Inhibitor Letrozole and Antiestrogen Fulvestrant in a Postmenopausal Breast Cancer Model Cancer Res., June 15, 2005; 65(12): 5439 - 5444. [Abstract] [Full Text] [PDF]

				G. J. Sabnis, D. Jelovac, B. Long, and A. Brodie The Role of Growth Factor Receptor Pathways in Human Breast Cancer Cells Adapted to Long-term Estrogen Deprivation Cancer Res., May 1, 2005; 65(9): 3903 - 3910. [Abstract] [Full Text] [PDF]

				A. Brodie, D. Jelovac, L. Macedo, G. Sabnis, S. Tilghman, and O. Goloubeva Therapeutic Observations in MCF-7 Aromatase Xenografts Clin. Cancer Res., January 15, 2005; 11(2): 884s - 888s. [Abstract] [Full Text] [PDF]

				D. Jelovac, L. Macedo, V. Handratta, B. J. Long, O. G. Goloubeva, J. N. Ingle, and A. M. H. Brodie Effects of Exemestane and Tamoxifen in a Postmenopausal Breast Cancer Model Clin. Cancer Res., November 1, 2004; 10(21): 7375 - 7381. [Abstract] [Full Text] [PDF]

				N. P. Nunez, D. Jelovac, L. Macedo, D. Berrigan, S. N. Perkins, S. D. Hursting, J. C. Barrett, and A. Brodie Effects of the Antiestrogen Tamoxifen and the Aromatase Inhibitor Letrozole on Serum Hormones and Bone Characteristics in a Preclinical Tumor Model for Breast Cancer Clin. Cancer Res., August 15, 2004; 10(16): 5375 - 5380. [Abstract] [Full Text] [PDF]

				B. J. Long, D. Jelovac, V. Handratta, A. Thiantanawat, N. MacPherson, J. Ragaz, O. G. Goloubeva, and A. M. Brodie Therapeutic Strategies Using the Aromatase Inhibitor Letrozole and Tamoxifen in a Breast Cancer Model J Natl Cancer Inst, March 17, 2004; 96(6): 456 - 465. [Abstract] [Full Text] [PDF]

				A. Thiantanawat, B. J. Long, and A. M. Brodie Signaling Pathways of Apoptosis Activated by Aromatase Inhibitors and Antiestrogens Cancer Res., November 15, 2003; 63(22): 8037 - 8050. [Abstract] [Full Text] [PDF]

				A. Brodie, D. Jelovac, and B. J. Long Predictions from a Preclinical Model: Studies of Aromatase Inhibitors and Antiestrogens Clin. Cancer Res., January 1, 2003; 9(1): 455s - 459s. [Abstract] [Full Text]

				Z. Fang, S. Yang, B. Gurates, M. Tamura, E. Simpson, D. Evans, and S. E. Bulun Genetic or Enzymatic Disruption of Aromatase Inhibits the Growth of Ectopic Uterine Tissue J. Clin. Endocrinol. Metab., July 1, 2002; 87(7): 3460 - 3466. [Abstract] [Full Text] [PDF]

				B. J. Long, D. Jelovac, A. Thiantanawat, and A. M. Brodie The Effect of Second-Line Antiestrogen Therapy on Breast Tumor Growth after First-Line Treatment with the Aromatase Inhibitor Letrozole: Long-Term Studies Using the Intratumoral Aromatase Postmenopausal Breast Cancer Model Clin. Cancer Res., July 1, 2002; 8(7): 2378 - 2388. [Abstract] [Full Text] [PDF]

				B. J. Long, D. N. Grigoryev, I. P. Nnane, Y. Liu, Y.-Z. Ling, and A. M. Brodie Antiandrogenic Effects of Novel Androgen Synthesis Inhibitors on Hormone-dependent Prostate Cancer Cancer Res., December 1, 2000; 60(23): 6630 - 6640. [Abstract] [Full Text]

				B. Sukhu, B. Rotenberg, C. Binkert, H. Kohno R. ZOHAR, C. A. G. McCulloch, and H. C. Tenenbaum Tamoxifen Attenuates Glucocorticoid Actions on Bone Formation in Vitro Endocrinology, August 1, 1997; 138(8): 3269 - 3275. [Abstract] [Full Text] [PDF]